CAR-T cell therapy, an advanced form of immunotherapy has received approval from Drug Controller General of India (DCGI) for commercial use in India. Now, the acute lymphoblastic leukaemia and lymphoma type have hope to be curable. The CAR-T therapy uses the patient’s own genetically modified cells to recognize and attack tumour cells.
Leave a Reply